EP Patent

EP4656193A1 — Pharmaceutical composition for treating tumors

Assigned to Eisai R&D Management Co Ltd · Expires 2025-12-03 · 0y expired

What this patent protects

Disclosed is a pharmaceutical composition for treating tumors, which comprises (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-l-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxami…

USPTO Abstract

Disclosed is a pharmaceutical composition for treating tumors, which comprises (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-l-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide represented by formula (I) or a pharmaceutically acceptable salt thereof and is administered in combination with an MEK inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
EP4656193A1
Jurisdiction
EP
Classification
—
Expires
2025-12-03
Drug substance claim
No
Drug product claim
No
Assignee
Eisai R&D Management Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.